- Home
- INM vs SNN Comparison
INM vs SNN Comparison
Compare INM & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INM | SNN |
|---|---|---|
| Founded | 1981 | 1856 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 12.3B |
| IPO Year | 2020 | 2002 |
Fundamental Metrics
Financial Performance| Metric | INM | SNN |
|---|---|---|
| Price | $1.36 | $27.60 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $36.25 |
| AVG Volume (30 Days) | 70.6K | ★ 1.7M |
| Earning Date | 05-12-2026 | 03-16-2026 |
| Dividend Yield | N/A | ★ 2.48% |
| EPS Growth | ★ 62.68 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,942,633.00 | N/A |
| Revenue This Year | N/A | $8.58 |
| Revenue Next Year | N/A | $5.60 |
| P/E Ratio | ★ N/A | $64.97 |
| Revenue Growth | ★ 7.50 | N/A |
| 52 Week Low | $0.58 | $27.23 |
| 52 Week High | $2.50 | $37.51 |
Technical Indicators
Market Signals| Indicator | INM | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 48.40 | 36.68 |
| Support Level | $1.35 | $27.23 |
| Resistance Level | $1.40 | $31.36 |
| Average True Range (ATR) | 0.07 | 0.53 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 47.04 | 15.65 |
Price Performance
Historical ComparisonAbout INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.